Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Market Research Report||Molecular Diagnostics Markets||Aarkstore Enterprise

Posted May 10 2011 9:56am

The technologies that constitute molecular diagnostics-like first-generation amplification, DNA probes, fluorescent in situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors, and molecular labels--are influencing the discovery of therapeutic molecules, the screening and diagnosis of patients, and the optimization of drug therapy. In the past few years, this rapidly evolving field has seen several fascinating developments. This Company Publications report describes the specific market segment of the in vitro diagnostics market known as molecular diagnostics and includes all of the generally accepted clinical analytical activities in use today. It examines the prevalent clinical-measurement devices, as well as their reagents and supplies as utilized in hospitals, clinics, large reference laboratories and doctor’s offices. Diagnostic tests marketed primarily as over-the-counter are generally not included in this report, although there is inevitably some overlap. The main objectives of this analysis are: 1) identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing; 2) obtaining a complete understanding of the chief molecular diagnostics tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic--from their basic principles to their applications; 3) discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; and 4) focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts.


Table of Contents :

1. Overview 12
1.1 Statement of Report 12
1.2 About This Report 12
1.3 Scope of the Report 13
1.4 Objectives 13
1.5 Methodology 14
1.6 Executive Summary 15
2. Introduction to Molecular Diagnostics and PCR Technology 19
2.1 Introduction to Genomics and Its Opportunity 19
2.2 Impact of the Human Genome Project on Molecular Diagnostics 21
2.3 Key Considerations for Molecular Diagnostics 21
2.4 Molecular Diagnostics in the Post-Genomic Era 23
2.5 Advances in Molecular Diagnostics Technologies 24
2.6 Genetic Variability and Disease 25
2.7 Major Technology Platforms 25
2.7.1 Gene-based Amplification Technologies 28
2.7.2 Detection of Amplified Gene Products 28
2.7.3 Target-based Gene Amplification 29
2.7.3.1 Polymerase Chain Reaction (PCR) 29
2.7.3.2 Real-Time PCR 29
2.7.3.3 Nucleic Acid Sequence-based Amplification (NASBA) 30
2.7.4 Probe-based Amplification 30
2.7.4.1 Ligase Chain Reaction (LCR) 30
2.7.4.2 Strand Displacement Amplification (SDA) 31
2.7.4.3 QB-Replicase Amplified Probe Assay 31
2.7.5 Signal-based Amplification 31
2.7.5.1 Branched DNA (bDNA) 31
2.7.6 Other Gene Amplification Technologies 32
2.7.6.1 Immuno-PCR (IPCR) 32
2.7.6.2 Bio-Barcode Amplification Assay (BCA) 32
2.7.6.3 Hybrid Capture 33
2.7.7 Next Generation Sequencing 33
3. Nucleic Acid Test Applications 35
3.1 Molecular Diagnostic Testing and Infectious Diseases 36
3.1.1 Genomics Molecular Diagnostics Market 37
3.1.1.1 Methods for DNA Detection and Gene Sequencing 48
3.1.1.2 Products and Applications 50
3.1.1.3 Oncology 51
3.1.2 SNPs and Genes: Medical Utility (Clinical Applications) 51
3.1.2.1 Clinical Application Initiatives 53
3.1.2.2 Sampling of Affymetrix's Clinical Application Collaborations 54
3.2 Infectious Disease Testing Using Molecular Diagnostics 56
3.2.1 HIV 62
3.2.2 Hepatitis Serologic Markers and Nucleic Acid Testing 67
3.2.2.1 Hepatitis A Virus (HAV) 67
3.2.2.2 Hepatitis B Virus (HBV) 68
3.2.2.2.1 Hepatitis B Market Size 73
3.2.2.3 Hepatitis C Virus (HCV) 74
3.2.2.4 Hepatitis D Virus (HDV) 80
3.2.2.5 Hepatitis E Virus (HEV) 80
3.2.3 Human Papillomavirus (HPV) 82
3.2.4 Influenza Viruses 87
3.2.4.1 H5N1 Influenza Virus 87
3.2.4.2 H1N1 Influenza Virus 89
3.2.5 Cancer Detection Using Molecular Diagnostics 91
3.2.5.1 Lung Cancer 92
3.2.5.2 Oral Cancer 92
3.2.5.3 Prostate Cancer 92
3.2.5.3.1 PCA3 92
3.2.5.3.2 Companies Active in Molecular Diagnostics and Prostate Cancer Analysis 93
3.2.5.4 Chronic Myelogenous Leukemia 95
3.2.5.5 Malignant Gliomas 96
3.2.5.6 Colorectal Cancer 96
3.2.5.6.1 Background on KRAS Mutation 96
3.2.5.7 Breast Cancer 100
3.2.5.8 Bladder Cancer 103
3.2.5.9 Ovarian Cancer 103
3.2.5.10 Molecular Diagnostic Screening Test for Cancer 104
3.2.5.11 Cervical Cancer 104
3.2.6 Microbiology Testing Using Molecular Diagnostics 104
3.2.6.1 Chlamydia 106
3.2.6.1.1 Revenue Forecasts 108
3.2.6.2 Gonorrhea 109
3.2.6.3 Tuberculosis (TB) 111
3.2.6.4 Group B Streptococcus (GBS) 113
3.2.6.5 Bordetella pertussis 116
3.2.6.6 Legionella pneumophila 117
3.2.6.7 Periodontal Bacteria 117
3.2.6.8 Pneumocystis carinii 117
3.2.6.9 Methicillin-resistant Staphylococcus Aureus (MRSA) 117
3.2.6.10 Clostridium difficile 118
3.2.6.11 Vancomycin-resistant Enterococci (VRE) 119
3.2.6.12 Fungal Infections 121
3.2.6.13 Herpes 121
3.2.6.14 Other Infectious Diseases 122
3.2.7 Blood Screening Using Molecular Diagnostics 122
3.2.7.1 Blood Screening Competitive Positions 123
3.3 Genetics Testing in Molecular Diagnostics 128
3.3.1 Functional Genomics 137
3.3.2 Genetic and Paternity Testing 138
3.4 Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics 139
3.4.1 The Market 139
3.4.2 Detection of Helicobacter pylori by PCR 142
3.4.3 Detection of Escherichia coli 0157 142
3.4.4 Detection of Enteric Viruses 143
3.4.5 Industrial Microorganisms 143
3.5 Molecular Diagnostics Forensics Testing Market 143
3.5.1 Analysis by PCR-based DNA Typing 144
3.5.2 Rapid Isolation of DNA for Restriction Fragment Length Polymorphism (RFLP) and PCR 145
3.5.3 DNA for PCR-STR Typing 145
3.6 Bioterrorism and Molecular Diagnostics 145
3.6.1 Introduction 145
3.6.1.1 Current Biological Threat Detection Systems 148
3.6.1.2 Use of DNA Microarrays and Biochips for Gene Expression Profiles in BWAs 149
3.6.1.3 Advantages and Disadvantages of Host Gene Expression Profiling as a Biothreat Detection 149
3.6.2 Biological Warfare Agents (BWAs) 150
3.6.2.1 Anthrax 151
3.6.2.2 Botulinum Toxin 152
3.6.2.3 Ricin 152
3.6.2.4 IVD Industry and Bioterrorism Preparedness 152
3.6.2.4.1 Brucellosis 152
3.6.2.4.2 Cholera 153
3.6.2.5 Rapid Lateral Flow Immunoassays 154
3.6.2.6 Biosensors 154
3.6.3 Anthrax in Clinical Samples 156
3.6.3.1 Overview of Anthrax and its Infectivity 156
3.6.3.2 Rapid Tests 157

For more information, please visit :

http://www.aarkstore.com/reports/Molecular-Diagnostics-Markets-1336.html

Contact: Sanaa

Ph.No.91927282585

Tel. No. +912227453309

Email:jenniffer@aarkstore.com

URL:http://www.aarkstore.com/

Post a comment
Write a comment:

Related Searches